Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-06-18-Speech-1-216"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070618.19.1-216"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Madam President, there are around 60 000 MS sufferers in Poland, which ranks Poland in third place after Germany and the United Kingdom. However, in those countries, around 30% of sufferers have access to immunomodulating therapy, whereas in Poland barely over 2% of patients can obtain this treatment. This is mainly due to a lack of funding and it is a problem that also affects the treatment of many other diseases, including cancer.
MS is currently an incurable disease, resulting from an impaired immune system, which leads to damage of the myelin sheath. Immunomodulating treatment is expensive, as is physiotherapy.
In Poland, any resolutions passed are not implemented mainly due to economic reasons and the crisis in the health service, the transformation of which has resulted in poor organisation and privatisation. The costs of medicines produced by Western companies are also prohibitively high. In my opinion, the European Parliament could try to influence these companies to prevent them from exploiting poorer patients and taking away their basic human right, namely the right to protect their health and to have access to medical treatment."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples